Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Go back to Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients| Regeneron (NASDAQ: REGN) | Delayed: 927.89 +109.12 (13.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $818.77 | 52 Week High | $592.36 | |||
| Open | $869.43 | 52 Week Low | $325.35 | |||
| Day High | $935.35 | P/E | 243.54 | |||
| Day Low | $839.08 | EPS | $3.81 | |||
| Volume | 2,870,901 | |||||
| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 11.19 -0.42 (3.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.61 | 52 Week High | $5.58 | |||
| Open | $11.38 | 52 Week Low | $3.60 | |||
| Day High | $11.39 | P/E | N/A | |||
| Day Low | $11.12 | EPS | $0.00 | |||
| Volume | 10,251,707 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 44.34 +1.21 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.13 | 52 Week High | $44.76 | |||
| Open | $44.82 | 52 Week Low | $36.81 | |||
| Day High | $45.30 | P/E | N/A | |||
| Day Low | $44.23 | EPS | $0.00 | |||
| Volume | 15,302,156 | |||||



